Regeneron was granted a patent for bispecific antibodies targeting tumors.

{
  "signal_id": "4a5b8e08-ca7d-51d3-99aa-1fb93632410b",
  "signal_type": "patents-company",
  "signal_subtype": "patentGrant",
  "detected_at": "2026-09-30T16:59:02+00:00",
  "company": {
    "name": "Regeneron",
    "domain": "regeneron.com"
  },
  "data": {
    "cpc": [
      {
        "code": "C07K 16/2887"
      },
      {
        "code": "C07K 16/2803"
      },
      {
        "code": "C07K 16/2809"
      },
      {
        "code": "A61K 2039/505"
      },
      {
        "code": "C07K 2317/24"
      }
    ],
    "tags": [
      "Intellectual Property",
      "Research & Development",
      "Pharmaceuticals",
      "Medical Research"
    ],
    "detail": "In September 2026 Regeneron patented antibody treatments designed to direct T cells against cancer cells while limiting unwanted immune activity, for oncology research and therapy.",
    "summary": "Regeneron was granted a patent for bispecific antibodies targeting tumors.",
    "event_at": "2026-09-29",
    "inventors": [
      {
        "name": "Eric Smith",
        "status": "unresolved",
        "is_primary": true
      },
      {
        "name": "Samuel Davis",
        "status": "resolved",
        "is_primary": false,
        "linkedin_url": "https://www.linkedin.com/in/samuel-davis-0225316"
      },
      {
        "name": "Bindu Varghese",
        "status": "resolved",
        "is_primary": false,
        "linkedin_url": "https://www.linkedin.com/in/bindu-varghese"
      },
      {
        "name": "Jessica R. Kirshner",
        "status": "resolved",
        "is_primary": false,
        "linkedin_url": "https://www.linkedin.com/in/jessica-kirshner-4533b8"
      },
      {
        "name": "Gavin Thurston",
        "status": "resolved",
        "is_primary": false,
        "linkedin_url": "https://www.linkedin.com/in/gavin-thurston-77518219b"
      }
    ],
    "event_kind": "grant_date",
    "grant_date": "2026-09-29",
    "source_url": "https://patents.google.com/patent/US12747300",
    "cpc_primary": {
      "code": "C07K 16/2887"
    },
    "patent_title": "Methods and antibody compositions for tumor treatment",
    "patent_number": "US12747300",
    "uspto_assignee": "Regeneron Pharmaceuticals, Inc.",
    "patent_abstract": "The present invention provides bispecific antibodies that bind to CD3 and tumor antigens and methods of using the same. According to certain embodiments, the bispecific antibodies of the invention exhibit reduced effector functions and have a unique binding profile with regard to Fcγ receptors. The bispecific antibodies are engineered to efficiently induce T cell-mediated killing of tumor cells. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, a second antigen-binding molecule that specifically binds human CD20, and an Fc domain that binds Fcγ receptors with a specific binding pattern. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of B-cell or melanoma tumors expressing CD20. The bispecific antibodies of the invention are useful for the treatment of various cancers as well as other CD20-related diseases and disorders.",
    "precision_class": "structural",
    "invention_explanation": "Engineered antibodies that attach to both T cells and tumor markers, bringing the cells together to destroy cancer while reducing other immune effects.",
    "technologies_mentioned": [
      "bispecific antibodies",
      "immuno-oncology",
      "T-cell therapies",
      "Fc receptor engineering"
    ]
  }
}

curl https://signals.autobound.ai/v1/signals/4a5b8e08-ca7d-51d3-99aa-1fb93632410b \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"regeneron.com","limit":20}'